Therapeutic area intelligence for Endothelin Receptor Antagonist with 3 indexed intelligence signals across regulatory, clinical, competitive, and market developments.

Signals: 3
Catalysts: 0
Companies: 2

Companies

Natco Pharma →

Watson Labs →

Assets

Bosentan →

Recent signals(3)

RegulatoryJuly 26, 2026

FDA Submission Update for Bosentan by Zydus Pharms

Zydus Pharms has submitted a supplemental application for Bosentan under ANDA207760, currently under standard review.

RegulatoryJuly 26, 2026

FDA Grants AP Status for Bosentan ANDA207110 by Watson Labs

The FDA has granted approval status (AP) for Watson Labs' ANDA207110 for Bosentan.

RegulatoryJune 27, 2026

FDA Accepts Supplement Application for Bosentan by Natco Pharma

The FDA has accepted a supplemental application for Bosentan submitted by Natco Pharma.

Upcoming catalysts

No catalysts indexed for this entity yet.

Indications

No related entities indexed yet.

Newsletter

Get signals before the market moves

Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.

No paywall. No spam. Unsubscribe anytime.